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Introduction {#s1}
============

Numerous studies have evaluated the association of tobacco smoke, a complex mixture of compounds, with several epigenetic marks, in particular with blood DNA methylation (DNAm) ([@c35]; [@c41]; [@c79]; [@c85]; [@c94]; [@c100]; [@c107]). For instance, DNAm of multiple CpGs (methylation sites) in the *AHRR* \[Aryl Hydrocarbon Receptor Repressor, which mediates dioxin toxicity and is involved in cell growth and differentiation ([@c34])\] and *F2RL3* \[coagulation factor II receptor-like 3, also known as PAR-4, which plays a role in blood coagulation, inflammation, and response to pain, ([@c36])\] genes has been associated with former and current smoking status, cumulative smoking, and shorter time since smoking cessation in several studies ([@c8]; [@c10]; [@c27]; [@c29]; [@c40]; [@c71]; [@c109]). In addition to *AHRR* and *F2RL3*, other genes have also been consistently and specifically associated with smoking in methylome-wide epidemiological studies investigating as many as 450,000 CpGs ([@c29]; [@c40]). The potential epigenetic effects of individual environmental toxicants in tobacco, however, remain largely unexplored.

Cadmium (Cd) is one of the main metals found in cigarettes ([@c62]; [@c90]). Its concentrations are extremely high in comparison with those from other metals such as arsenic or lead ([@c15]). It is one of the most relevant heavy metals in terms of potentially explaining adverse health effects of smoking because it has been associated with tobacco-related health outcomes, including cardiovascular disease (CVD) and cancer ([@c1]; [@c3]; [@c30]; [@c57]). Increased exposure to Cd has been associated with differences in global DNAm in human ([@c74]) and animal ([@c60]; [@c82]) studies, possibly related to Cd-induced alterations of DNA methyltransferases ([@c6]; [@c39]; [@c68]; [@c87]; [@c106]) and ten-eleven translocation (TET) ([@c70]; [@c104]) enzymes activity. Some reports have suggested that TETs activity is influenced by oxidative stress ([@c19]). Cd has been related to oxidative stress ([@c14]; [@c22]; [@c46]; [@c54]; [@c81]) and could interfere in the DNAm pathways by promoting redox unbalance. We hypothesized that Cd exposure from tobacco could induce changes in genomic DNAm and mediate well-known smoking-related methylation alterations. *In vitro* and *in vivo* studies have shown both gene-specific hypermethylation and hypomethylation in relation to Cd exposure ([@c37]; [@c76]; [@c98]; [@c99]; [@c108]). The number of studies evaluating the association of Cd exposure with differences in CpG-specific DNAm in humans, however, is not sufficient ([@c74]).

Participants of the Strong Heart Study (SHS), a prospective cohort that includes 13 American Indian tribes, have substantially higher concentrations of urinary Cd in comparison with other large studies, such as the Multi-Ethnic Study of Atherosclerosis (MESA) and National Health and Nutrition Examination Survey (NHANES) ([@c18]). Cd exposure in the SHS was previously associated with smoking-related health effects, including total, lung, and pancreas cancer mortality ([@c30]); incident peripheral arterial disease ([@c89]); and incident CVD ([@c88]). The objective of this research was to conduct an epigenome-wide association study (EWAS) of Cd and smoking exposure with differences in human blood DNAm profiles. As a secondary objective, we assessed the implication of findings to relevant DNAm and demethylation pathways and evaluated whether the smoking-related increase in urine Cd levels can explain the association between smoking and genomic DNAm profiles. To achieve these aims, we evaluated the association of urinary Cd and smoking (self-reported active and former smoking, and cumulative smoking dose) with blood DNAm in 790,026 CpGs determined with the Infinium Methylation EPIC array in the SHS. We used a causal inference mediation approach ([@c66]) to estimate how much of the DNAm changes associated with smoking can be independently attributed to smoking-related increases in Cd exposure, as measured in urine (an established biomarker of Cd internal dose). In addition, the association analyses were followed by a gene set and molecular regulatory elements enrichment and *in silico* evaluation of relevant biological pathways for Cd and smoking influences in DNAm metabolism.

Methods {#s2}
=======

Study Population {#s2.1}
----------------

The SHS is a prospective cohort study funded by the National Heart, Lung, and Blood Institute to investigate CVDs and its risk factors in American Indian adults ([@c47]). In 1989--1991, a total of 4,549 men and women ages 45--75 y who were members of 13 tribes based in Arizona, Oklahoma, North Dakota, and South Dakota accepted invitations to participate. All individuals were asked to fast overnight (8 h or more). Participants without sufficient urine for metal analyses were excluded ($n = 576$) (Figure S1). Due to tribal request, samples from one of the tribes were not selected for DNAm analyses, leaving 3,516 participants. Among them, participants who were free of CVD and not missing urinary metals or other variables of interest at baseline (1989--1991) were eligible for blood DNAm analyses ($n = 3,106$). Sufficient blood was available for DNAm analysis in 2,351 participants. After laboratory analyses, we removed data from 18 individuals without classical bimodal distribution in DNAm levels and from 8 individuals with low median intensity levels, leaving a total of 2,325 participants for this study. These participants were similar to those eligible in sociodemographic and anthropometric characteristics (Table S1).

Participant Characteristics and Self-Reported Smoking {#s2.2}
-----------------------------------------------------

Trained and certified nurses and medical examiners collected information on sociodemographic factors (age, sex, study region, education level), medical history, smoking status (never, former, current), and cumulative smoking dose (cigarette pack-years) in a personal interview. Participants having $\text{smoked} \geq 100$ cigarettes in their lifetime and smoking at the time of the interview were considered current smokers. Noncurrent smokers who had $\text{smoked} > 100$ cigarettes in their lifetime were classified as former smokers. Cigarette pack-years were calculated as the number of 20-cigarette packs smoked per day times the number of years the person smoked, with zero assigned to never smokers. The trained nurses and medical examiners conducted a physical exam, including anthropometric measures \[height and weight to measure body mass index (BMI)\], and collected fasting blood and spot urine samples. Plasma creatinine was measured by an alkaline picrate rate method ([@c47]). We calculated estimated glomerular filtration rate (eGFR) from recalibrated plasma creatinine, age, and sex using the Chronic Kidney Disease -- Epidemiology Collaboration formula ([@c50]).

Urinary Cadmium Determinations {#s2.3}
------------------------------

Morning spot urine samples were collected in polypropylene tubes, frozen within 1 to 2 h of collection, shipped buried in dry ice, and stored at $- 70{^\circ}C$ in the Penn Medical Laboratory, MedStar Research Institute, Washington, DC, USA. In 2009, urine samples were shipped to the Trace Metals Laboratory at Graz University, Austria, to measure Cd and other metals using inductively coupled plasma--mass spectrometry (ICP-MS) (Agilent 7700x ICP--MS; Agilent Technologies). The limit of detection (LOD) for urine Cd was $0.015\;\mu g/L$. In one participant below the LOD, the Cd concentration was imputed as the LOD divided by the square root of two. Urine Cd concentrations were corrected for molybdenum oxide interference. Other laboratory details and extensive quality control/quality assurance have been published ([@c77]). To account for urine dilution, urine Cd concentrations were expressed in micrograms per gram of urine creatinine. Urine creatinine was measured at the Laboratory of the National Institute of Diabetes and Digestive and Kidney Disease, Epidemiology and Clinical Research Branch (Phoenix, Arizona, USA) by an alkaline picrate rate method.

Microarray DNAm Determinations {#s2.4}
------------------------------

Buffy coats from fasting blood samples were collected in 1989--1991, at the same time as the collection of urinary samples for Cd measures and of physical examination and interview for the assessment of baseline smoking status and sociodemographic variables. Biological specimens were stored at $- 70{^\circ}C$. DNA from white blood cells was extracted and stored at the Penn Medical Laboratory, MedStar Health Research Institute under a strict quality-control system. In 2015, blood DNA was shipped to the analytical laboratory at the Texas Biomedical Research Institute for DNAm analysis. DNA was bisulfite-converted with the EZ DNAm kit (Zymo Research) according to the manufacturer's instructions. Bisulfite-converted DNA was measured using the Illumina MethylationEPIC BeadChip (850K), which provides a measure of DNAm at a single nucleotide resolution at $> 850,000$ CpGs. Samples were randomized across and within plates to remove potential batch artifacts and confounding effects, and replicate and across-plate control samples were included on every plate. All the preprocessing was conducted using R version 3.6.1. Data were read in six different batches (of $\sim 400$ individuals each) and combined using the R package minfi (version 1.18.4). CpGs with a *p*-detection value greater than 0.01 in more than 5% of the individuals (6,159 CpGs) were removed. Single sample normalization was conducted using the preprocessNoob function in R package minfi ([@c28]; [@c93]), which includes a background correction with dye-bias normalization for Illumina Infinium methylation arrays. As a result of these preprocessing preliminary analyses, we had data from 2,325 individuals and 860,079 CpGs. Cross-hybridizing probes, sex chromosomes, and SNP probes with minor allele frequency $> 0.05$ ([@c52]) were removed for analysis. The final number of CpGs for analysis was 790,026. Quality checks, data normalization, statistical preprocessing, and beta-value calculation, which ranges from 0 to 1 and represents the proportion of unconverted cytosines (Cs) in bisulfite-converted DNA at specific locations, were performed using the R package minfi ([@c28]). We estimated Houseman cell proportions (CD8T, CD4T, NK, B cells, monocytes, and granulocytes), also using the R package minfi, to use them as adjustment variables in the regression models. We detected and corrected for potential batch effects by sample plate, sample row, and DNA isolation time with the combat function (*sva* R package). We conducted annotation of CpGs to the nearest gene according to the Illumina Infinium MethylationEPIC Manifest File (version 1.0 B4) ([@c28]; [@c38]).

Statistical Methods {#s2.5}
-------------------

### DMPs. {#s2.5.1}

Four predictors of DMPs were assessed in separate analyses: total urinary Cd concentrations (log-transformed in $\mu g/g$ of creatinine units), current smoking status (vs. never smoking), former smoking status (vs. never smoking), and cumulative smoking dose (pack-year units). Beta values (i.e., DNAm proportions at a given CpG) were converted into *M* values (logit transformation of DNAm proportions) before conducting linear regression models as implemented with the R package limma (version v3.28.14). Empirical Bayes shrinkage (conducted by limma) has been reported to work better in *M* values than in beta values due to the heteroscedastic nature of the beta values ([@c91]). In addition, the logistic transformation monotonically maps values in the interval (0,1) to the whole real line ($- \infty,\infty$) and has been previously used to transform proportion data to fulfill linear modeling assumptions ([@c12], [@c102]). Thus, we decided to logit-transform $\beta$ values and then apply linear regression. Models adjusted for biologically relevant variables: age at baseline, sex, study region, BMI, Houseman blood cell composition, and five principal components to account for genetic population stratification ([@c69]). We further adjusted for smoking status (never, former, current) and eGFR in Cd models. We accounted for multiple comparisons by controlling for an FDR ([@c72]) at a 0.05 cutoff. Genomic inflation can lead to inflated *p*-values and false positives in EWAS studies ([@c97]), and it was addressed by calculating a set of surrogate variables (SVs) ([@c48]) from fully adjusted Cd and smoking models using the R package SmartSVA (version 0.1.3) to estimate SVs out of the unexplained DNAm variability and further adjusting the models for them. Although in subsequent bioinformatic analysis we focused on DMPs at an FDR-corrected threshold of statistical significance of 0.05, in the supplementary material we provide the full EWAS output, including nonstatistically significant DMPs (Excel Tables S1--S4).

### Mediation analysis. {#s2.5.2}

The main question addressed by causal mediation analysis is to what extent is the total effect of changing an exposure *E* mediated by an intermediate variable *M* on the causal pathway to outcome *Y* (the indirect effect) and to what extent is the effect not mediated by *M* (the direct effect) ([@c66]; [@c96]). In our mediation framework the "exposure" *E* of interest is smoking, a surrogate for many toxic compounds in tobacco. We know that smoking is an important predictor of DNAm (outcome *Y*), and being a current or former smoker as well as accumulated smoking are related to changes in site-specific DNAm, independently of age, sex, and confounders, in comparison with never smokers. The intermediate variable *M* that we are specifically interested in investigating is urinary Cd, a well-established exposure biomarker, because smoking can cause changes in Cd biomarkers through direct intake through the lungs. Alternatively, the association of Cd biomarker to DNAm is substantiated based on published experimental studies reporting that increased exposure to Cd induces differences in DNAm.

We used the "product of coefficients" method ([@c66]) to assess the contribution of increase in urinary Cd concentrations from smoking (current, former, and cumulative smoking in separate models) to the corresponding absolute change in DNAm proportions at specific CpGs (i.e., smoking-related changes in DNAm proportions mediated by Cd). First, for the outcome models, because collapsibility is required for mediation analysis ([@c96]), we used beta regression with an identity link for additively modelling untransformed methylation proportions (instead of the *M*-values) in a generalized linear regression setting with the mgcv package (version 1.8-31) of the R software. Specifically, we fitted beta regression models for DNAm (dependent variable in separate models for each CpG that was significant at 0.05 FDR-corrected *p*-values for Cd and current smoking (excluding former smokers), for Cd and former smoking (excluding current smokers), and for Cd and pack-years, by smoking variables and log-transformed urine Cd (independent variables) and confounders (age, sex, BMI, eGFR, study center, cell counts, and genetic principal components). Second, for the mediator model, we fitted linear regression models for log-transformed urine Cd concentration (dependent variable) by smoking variables (i.e., current and former smoking and pack-years as independent variables in separate models) and the same confounders included in the outcome model. Third, we calculated the effect of smoking on DNAm mediated through Cd (i.e., "indirect" effect) as the product of the mean change in log-Cd concentrations by smoking (smoking regression coefficient from the mediator model) and the absolute change in methylation percentages associated with log-transformed Cd concentrations (Cd regression coefficient from the outcome model). Mediated effects were expressed as the absolute amount of the smoking-associated change in DNAm attributable to Cd ("absolute mediated effect"), as well as the percentage of the smoking-associated change in DNAm attributable to Cd out of the "total effect," defined as the sum of the indirect and direct effects ("relative mediated effect"). Additionally, 95% confidence intervals were derived by simulation from the estimated model coefficients and covariance matrices (adapted from [@c44]).

### Sensitivity analyses. {#s2.5.3}

We conducted a number of sensitivity analyses. First, we repeated the models for the top 25 significant DMPs for current vs. never smokers in analyses stratified by center and sex. Second, we repeated the DMP analysis for the six significant DMPs for urinary Cd restricting the analysis to never smokers, to assess whether the association between Cd and DNAm was only reflecting smoking status. Third, as we do not have cotinine measurements in this study and smoking is a self-reported variable, we used the EpiSmokEr tool ([@c9]) to predict smoking status based on DNAm data. Fourth, we reran the Cd models excluding the eGFR variable as well as additionally adjusting for specific gravity. Last, because probe type bias might be an issue, we applied Regression on Correlated Probes (RCP) normalization after snoob normalization as implemented by the R package ENmix (version 1.8.0) ([@c61]) to see whether the results changed.

### Enrichment analyses. {#s2.5.4}

Among Cd- and smoking-related DMPs with a FDR-corrected *p*-value $< 0.05$, we conducted a hypergeometric analysis to identify enriched gene sets using Kyoto Encyclopedia of Genes and Genomes (KEGG) ([@c42]; [@c43]) and Gene Ontology (GO) ([@c4]; [@c92]) as conducted by the gometh function of the Bioconductor missMethyl package (version 1.6.2) ([@c67]). Among DMPs with a nominal $p\text{-value} < 10 \times 10^{- 5}$, we additionally investigated enrichment for molecular regulatory elements of statistically significant DMPs in comparison with nonstatistically significant DMPs, including annotated functional gene regions (TSS1500 and TSS200, 5′UTR, 1 st Exon, Gene body, and 3′UTR) and regions defined by the CpG density context (Open Sea, N-shelf, N-shore, Island, S-shore, and S-shelf). Similarly, we also investigated enrichment for 15-chromatin states retrieved from the ROADMAP Epigenomics Mapping Consortium (ChromHMM version 1.10) ([@c7]; [@c24]; [@c73]). The mapping of DNAm changes to the most probable chromatin state (combination of histone marks associated to varying degrees of expression) using ChromHMM is a way to identify DNA regulatory activity in a tissue-specific manner, including coding and noncoding portions of the genome, which provides potential functional mechanisms to EWAS findings. For regulatory elements enrichment analysis, *p*-values were corrected using the Bonferroni method considering 15 chromatin states, 6 categories relatives to functional gene region, and 6 categories relative to CpG density context.

### Molecular characterization and *in silico* protein-network analysis of DNAm metabolism. {#s2.5.5}

To conduct the molecular characterization of DNAm metabolism we searched KEGG ([@c42]) public database for key pathways directly or indirectly related to DNAm (including factors related to methyl groups' depletion) as of 26 June 2019, using the following descriptors: "Glutathione metabolism" (hsa00480), "Citrate cycle" (hsa00020), "One carbon pool by folate" (hsa00670), "Selenocompound metabolism" (hsa00450), and "Cysteine and methionine metabolism" (hsa00270). The search strategy retrieved a total of 158 proteins. TET1, TET2, TET3, SELENOP, AICDA, TDG, and APEX1 genes were not retrieved by our search strategy, but we manually added them to the final list of key proteins because of their potential role in active DNA demethylation according to previous reports ([@c14]; [@c46]; [@c74]).

Subsequently, among DMPs with a FDR-corrected $p\text{-value} < 0.05$, we created a list of unique protein-coding genes attributed to Cd-DMPs and to the union of the identified smoking related-DMPs ([Figure 1](#f1){ref-type="fig"}). Finally, we constructed a protein interaction network of proteins encoded by the identified smoking and Cd-related genes with respect to the DNAm key proteins selected from the search strategy described above by obtaining protein interactions information from STRING database version 11.0 ([@c86]). The STRING database provides a confidence score (from 0 to 1) to indicate the estimated likelihood that the annotated interaction between a given pair of proteins is biologically meaningful, specific, and reproducible, according to the evidence derived from in-house predictions, homology transfers, and the externally maintained databases ([@c86]). We displayed protein interaction networks with Cytoscape (version 3.7.1) ([@c78]) using the yfiles Organic layout. As a result, 4 and 113 Cd and smoking-related nodes, respectively, were included in the network, in addition to the DNAm related-nodes, which included 159 nodes with high confidence scores (CHAC1, CHAC2, GSTT1, GSTT2, INMT and NAT8B nodes were excluded from the original list of 165 DNAm metabolism selected proteins because they showed connections with low confidence scores).

![Summary of results from the epigenome-wide association study of cadmium (Cd) and smoking with DNA methylation (DNAm) and subsequent bioinformatics analysis. After considering a false discovery rate (FDR)-corrected *p*-value \< 0.05, we obtained 6 Cd-differentially methylated positions (DMPs) and 312 smoking DMPs in a genomic exploration of $\sim 790,000$ CpG sites with the Infinium MethylationEPIC BeadChip. We excluded nonprotein-coding genomic regions and duplicate genes and conducted gene set enrichment analysis. We subsequently evaluated protein interaction networks among protein-encoding genes from the STRING database, resulting in a protein interaction network of 271 nodes and 1,802 interactions. We observed highly connected nodes, which were directly or indirectly related to DNAm metabolism key proteins.](ehp6345_f1){#f1}

Results {#s3}
=======

Descriptive Analysis {#s3.1}
--------------------

The prevalence of current and former smokers was 38.4% and 32.2%, respectively. Median interquartile range (IQR) accumulated smoking and urinary Cd levels were, respectively, 4 (0, 18) cigarette pack-years and 0.97 $\left( {0.62,\, 1.50} \right)\,\mu g/g$. Older participants had higher levels of Cd, as did women in comparison with men ([Table 1](#t1){ref-type="table"}). As expected, current smokers showed higher urine Cd concentrations. The difference in Cd levels between smoking status groups was statistically significant ($p\text{-value} < {2 \times 10}^{- 16}$, data not shown). The geometric mean ratio (GMR) of urine Cd comparing current and former smokers with never smokers was 1.45 \[95% confidence interval (CI): 1.39, 1.52\] and 1.10 (95% CI: 1.04, 1.17), respectively, in models adjusting for age, sex, BMI, center, and eGFR (data not shown). The corresponding GMR per a 10-pack--year increase was 1.10 (95% CI: 1.06, 1.14) (data not shown).

###### 

Median (IQR) of urine cadmium ($\mu g/g$) and accumulated smoking dose (pack-years) levels and percentage of former and current smoking status by participant's characteristics.

Table 1 has 4 columns, listing variables, components, cadmium in micrograms per gram, former smoking in percentage, current smoking in percentage, and cumulative smoking, pack-years.

  ---------------------------------------------------------------------------------------------------------------------------------------------
                                                 $N$     Cadmium ($\mu g/g$)   Former smoking (%)   Current smoking (%)   Cumulative smoking\
                                                                                                                          (pack-years)
  ---------------------------------------------- ------- --------------------- -------------------- --------------------- ---------------------
  Overall                                        2,325   0.97 (0.62, 1.50)     32.2                 38.4                  4 (0, 18)

  Age (y)                                                                                                                 

   $< 50$                                        669     0.89 (0.56, 1.31)     47.3                 56.9                  4 (0, 17)

   50--64                                        1,246   1.00 (0.64, 1.55)     32.6                 30.7                  3 (0, 18)

   $\geq 65$                                     410     1.03 (0.64, 1.59)     20.1                 12.4                  2 (0, 20)

  Sex                                                                                                                     

   Men                                           964     0.71 (0.47, 1.10)     51.1                 53.4                  9 (0, 27)

   Women                                         1,361   1.16 (0.77, 1.78)     48.9                 46.6                  1 (0, 12)

  Smoking status                                                                                                          

   Never                                         684     0.86 (0.54, 1.36)     0.0                  0.0                   0 (0, 0)

   Former                                        748     0.81 (0.55, 1.25)     100.0                0.0                   7 (2, 20)

   Current                                       893     1.17 (0.77, 1.81)     0.0                  100.0                 14 (5, 30)

  Center                                                                                                                  

   Arizona                                       312     0.76 (0.53, 1.19)     15.5                 6.3                   0 (0, 5)

   Oklahoma                                      981     0.86 (0.55, 1.33)     45.5                 37.3                  2 (0, 16)

   Dakota                                        1,032   1.11 (0.75, 1.78)     39.0                 56.4                  7 (0, 23)

  Obesity                                                                                                                 

   No                                            1,238   1.05 (0.66, 1.63)     44.8                 62                    6 (0, 23)

   Yes                                           1,087   0.87 (0.57, 1.35)     55.2                 38                    2 (0, 13)

  eGFR ($\text{ml}/\text{min}/1{.73\; m}^{2}$)                                                                            

   $< 60$                                        76      0.91 (0.53, 1.51)     32.89                32.89                 7 (2, 25)

   $\geq 60$                                     2,249   0.97 (0.62, 1.50)     32.15                38.59                 11 (3, 26)
  ---------------------------------------------------------------------------------------------------------------------------------------------

Note: IQR, interquartile range.

Differentially Methylated Positions {#s3.2}
-----------------------------------

We found differential methylation in 6 CpGs for urinary Cd at the FDR-corrected significance level of 0.05 ([Table 2](#t2){ref-type="table"}; Figure S2; Excel Table S1). Two CpGs (cg14391737 and cg17739917) were new from the Illumina Infinium MethylationEPIC array and therefore have not been reported before. One CpG was annotated to *AHRR*, one to *F2RL3*, one to *PRSS23*, two to *2q37.1*, and one to *RARA*. Among those six significant CpGs in the overall population, four remained significant after restricting the models to never smokers ([Table 2](#t2){ref-type="table"}). A total of 288 CpGs were differentially methylated in relation to current smoking ([Table 3](#t3){ref-type="table"}; Figure S2; Excel Table S2). A total of 149 CpGs were new from the Illumina Infinium MethylationEPIC array. The top DMPs annotated to smoking-related genes in a previous meta-analysis was replicated in our study ([Table 3](#t3){ref-type="table"}, [@c40]). Among the top 25 DMPs for current smoking ([Table 3](#t3){ref-type="table"}), 5 were annotated to *AHRR*, 2 to *F2RL3*, 1 to *PRSS23*, 3 to *2q37.1*, and 1 to *RARA*. A total of 17 CpGs were differentially methylated in relation to former smoking (8 of them were also associated with current smoking) (Figure S2; Table S2; Excel Table S3), 5 of them being new from the Illumina Infinium MethylationEPIC array. A total of 77 CpGs were differentially methylated in relation to cigarette pack-years \[62 of them also associated with current smoking (Figure S2; Table S3; Excel Table S4), and 29 of them being new from the Illumina Infinium MethylationEPIC array\]. The genomic inflation factors (GIF) associated with the nominal *p*-values for the Cd, current and former smoking, and pack-years analyses before SV adjustment were 1.49, 2.91, 1.02, and 1.30, respectively. In the final models, which included SVs adjustment, the corresponding GIFs were, respectively, 1.05, 1.02, 1.02, and 1.003.

###### 

Top differentially methylated positions (DMPs) associated to log-transformed urine cadmium (Cd) levels (i.e., Cd DMPs).

Table 2 has 7 main columns, listing CpGs, Chrs, positions, genes, Functions, Overall, and never smokers. The columns listing overall and never smokers are each divided into 3 sub columns, listing Odds ratios \[95 percent confidence intervals (C I)\], Nominal p-values, and FDR-corrected p-values.

  CpG                                            Chr     Position    Gene     Function                                                                             Overall             Never smokers                                                                  
  ---------------------------------------------- ------- ----------- -------- ------------------------------------------------------------------------------------ ------------------- ------------------------- ------------------------ ------------------- ------- -------
  cg14391737[^*b*^](#TF4){ref-type="table-fn"}   chr11   86513429    PRSS23   Encodes Serine protease 23. May be an important ovarian protease                     0.92 (0.9, 0.94)    $1.01 \times 10^{- 12}$   $6.18 \times 10^{- 7}$   0.94 (0.89, 0.98)   0.003   0.006
  cg21566642                                     chr2    233284661   2q37.1   Uncharacterized                                                                      0.92 (0.9, 0.94)    $1.56 \times 10^{- 12}$   $6.18 \times 10^{- 7}$   0.97 (0.92, 1.01)   0.1     0.2
  cg05575921                                     chr5    373378      AHRR     Mediates dioxin toxicity. Involved in cell growth and differentiation                0.84 (0.8, 0.88)    $1.12 \times 10^{- 11}$   $2.96 \times 10^{- 6}$   0.85 (0.77, 0.94)   0.002   0.006
  cg01940273                                     chr2    233284934   2q37.1   Uncharacterized                                                                      0.96 (0.94, 0.97)   $2.41 \times 10^{- 8}$    0.004                    0.98 (0.95, 1.02)   0.3     0.3
  cg03636183                                     chr19   17000585    F2RL3    Blood coagulation, inflammation, and response to pain                                0.96 (0.94, 0.97)   $1.60 \times 10^{- 7}$    0.02                     0.96 (0.93, 1.00)   0.03    0.04
  cg17739917[^*b*^](#TF4){ref-type="table-fn"}   chr17   38477572    RARA     Development, differentiation, apoptosis, granulopoeisis, clock genes transcription   0.95 (0.93, 0.97)   $2.63 \times 10^{- 7}$    0.03                     0.93 (0.88, 0.97)   0.002   0.006

Note: BMI, body mass index; CI, confidence interval; FDR, false discovery rate.

Linear regression models were fitted using logit-transformed DNAm proportions as dependent variables separately for each CpG and were adjusted for smoking status (never, former, current), age (years), sex (male/female), BMI (${{kg}/m}^{2}$), Houseman cell proportions (CD8T, CD4T, NK, B cells, monocytes and granulocytes), study center (Arizona, Oklahoma or North and South Dakota), five genetic principal components and estimated glomerular filtration rate ($\text{ml}/\text{min}/1{.73\; m}^{2}$).

Not available CpGs in the Illumina HumanMethylation450 BeadChip array.

###### 

Top 25 differentially methylated positions (DMPs) comparing current smoking status with never smoking status (i.e., current smoking-DMPs).

Table 3 has 10 columns, listing CpG, Chr, positions, genes, Functions, Odds ratios (95 percent C I), Nominal p-values, FDR p-values, FDR p-values in meta-analysis, and direction of association in meta-analysis.

  CpG          Chr     Position    Gene         Function                                                                             Odds ratio (95% CI)[^*a*^](#TF6){ref-type="table-fn"}   Nominal *p*-value         FDR *p*-value             FDR *p*-value in meta-analysis ([@c40])[^*b*^](#TF7){ref-type="table-fn"}   Direction of association in meta-analysis ([@c40])[^*b*^](#TF7){ref-type="table-fn"}
  ------------ ------- ----------- ------------ ------------------------------------------------------------------------------------ ------------------------------------------------------- ------------------------- ------------------------- --------------------------------------------------------------------------- --------------------------------------------------------------------------------------
  cg05575921   chr5    373378      AHRR         Mediates dioxin toxicity. Involved in cell growth and differentiation                0.38 (0.35, 0.42)                                       $1.99 \times 10^{- 99}$   $1.57 \times 10^{- 93}$   $6.1 \times 10^{- 22}$                                                      Inverse
  cg21566642   chr2    233284661   2q37.1       Uncharacterized                                                                      0.71 (0.69, 0.74)                                       $1.92 \times 10^{- 67}$   $7.58 \times 10^{- 62}$   $4.5 \times 10^{- 21}$                                                      Inverse
  cg01940273   chr2    233284934   2q37.1       Uncharacterized                                                                      0.8 (0.78, 0.83)                                        $1.37 \times 10^{- 58}$   $3.60 \times 10^{- 53}$   $9.8 \times 10^{- 30}$                                                      Inverse
  cg17739917   chr17   38477572    RARA         Development, differentiation, apoptosis, granulopoeisis, clock genes transcription   0.75 (0.73, 0.78)                                       $1.90 \times 10^{- 56}$   $3.75 \times 10^{- 51}$   Not available                                                               ---
  cg03636183   chr19   17000585    F2RL3        Blood coagulation, inflammation, and response to pain                                0.8 (0.78, 0.83)                                        $5.84 \times 10^{- 52}$   $9.23 \times 10^{- 47}$   $5.7 \times 10^{- 17}$                                                      Inverse
  cg26703534   chr5    377358      AHRR         Mediates dioxin toxicity. Involved in cell growth and differentiation                0.83 (0.81, 0.86)                                       $1.84 \times 10^{- 46}$   $2.42 \times 10^{- 41}$   $7.2 \times 10^{- 18}$                                                      Inverse
  cg21161138   chr5    399360      AHRR         Mediates dioxin toxicity. Involved in cell growth and differentiation                0.86 (0.84, 0.88)                                       $3.82 \times 10^{- 28}$   $4.31 \times 10^{- 23}$   $7.9 \times 10^{- 13}$                                                      Inverse
  cg25648203   chr5    395444      AHRR         Mediates dioxin toxicity. Involved in cell growth and differentiation                0.84 (0.81, 0.87)                                       $4.92 \times 10^{- 25}$   $4.86 \times 10^{- 20}$   $2.7 \times 10^{- 11}$                                                      Inverse
  cg09935388   chr1    92947588    GFI1         Transcriptional repressor. Plays a role in hematopoiesis and oncogenesis             0.75 (0.71, 0.79)                                       $6.17 \times 10^{- 25}$   $5.42 \times 10^{- 20}$   $7.0 \times 10^{- 14}$                                                      Inverse
  cg14391737   chr11   86513429    PRSS23       Encodes Serine protease 23. May be an important ovarian protease                     0.81 (0.78, 0.84)                                       $2.18 \times 10^{- 24}$   $1.72 \times 10^{- 19}$   Not available                                                               ---
  cg19859270   chr3    98251294    GPR15        Chemokine receptor for human immunodeficiency virus type 1 and 2                     0.84 (0.81, 0.87)                                       $2.99 \times 10^{- 24}$   $2.15 \times 10^{- 19}$   $6.3 \times 10^{- 17}$                                                      Inverse
  cg17287155   chr5    393347      AHRR         Mediates dioxin toxicity. Involved in cell growth and differentiation                0.78 (0.74, 0.82)                                       $2.16 \times 10^{- 23}$   $1.42 \times 10^{- 18}$   $1.1 \times 10^{- 13}$                                                      Inverse
  cg14753356   chr6    30720108    Intergenic   Uncharacterized                                                                      0.86 (0.83, 0.89)                                       $4.34 \times 10^{- 21}$   $2.64 \times 10^{- 16}$   $2.3 \times 10^{- 14}$                                                      Inverse
  cg16841366   chr2    233286192   2q37.1       Uncharacterized                                                                      0.83 (0.8, 0.87)                                        $5.54 \times 10^{- 21}$   $3.13 \times 10^{- 16}$   Not available                                                               ---
  cg18110140   chr15   75350380    Intergenic   Uncharacterized                                                                      0.87 (0.84, 0.9)                                        $6.71 \times 10^{- 20}$   $3.53 \times 10^{- 15}$   Not available                                                               ---
  cg21911711   chr19   16998668    F2RL3        Blood coagulation, inflammation, and response to pain                                0.85 (0.82, 0.88)                                       $1.26 \times 10^{- 19}$   $6.22 \times 10^{- 15}$   Not available                                                               ---
  cg25189904   chr1    68299493    GNG12        Modulator in transmembrane signaling systems                                         0.81 (0.78, 0.85)                                       $2.13 \times 10^{- 19}$   $9.90 \times 10^{- 15}$   $3.3 \times 10^{- 18}$                                                      Inverse
  cg22675726   chr18   3179889     MYOM1        Structural constituent of muscle. Associated with hypertrophic cardiomyopathy        0.85 (0.82, 0.88)                                       $4.70 \times 10^{- 19}$   $2.06 \times 10^{- 14}$   Not available                                                               ---
  cg00045592   chr1    160714299   SLAMF7       Modulator on the activation and differentiation of immune cells                      0.89 (0.86, 0.91)                                       $2.37 \times 10^{- 18}$   $9.87 \times 10^{- 14}$   Not available                                                               ---
  cg00475490   chr11   86517110    PRSS23       Encodes Serine protease 23. May be an important ovarian protease                     0.78 (0.74, 0.83)                                       $6.60 \times 10^{- 18}$   $2.61 \times 10^{- 13}$   Not available                                                               ---
  cg16522223   chr22   43400443    PACSIN2      Intracellular vesicle-mediated transport                                             0.93 (0.91, 0.94)                                       $3.23 \times 10^{- 17}$   $1.22 \times 10^{- 12}$   Not available                                                               ---
  cg09338374   chr22   39888390    Intergenic   Uncharacterized                                                                      1.1 (1.07, 1.12)                                        $6.59 \times 10^{- 17}$   $2.37 \times 10^{- 12}$   Not available                                                               ---
  cg15159987   chr19   17003890    CPAMD8       Innate and acquired immunity                                                         0.93 (0.91, 0.95)                                       $1.50 \times 10^{- 16}$   $5.16 \times 10^{- 12}$   $4.6 \times 10^{- 5}$                                                       Inverse
  cg21322436   chr7    145812842   CNTNAP2      Cell adhesion. Related to autism                                                     0.87 (0.84, 0.9)                                        $1.59 \times 10^{- 16}$   $5.25 \times 10^{- 12}$   $9.7 \times 10^{- 15}$                                                      Inverse
  cg26768182   chr9    134272679   Intergenic   Uncharacterized                                                                      0.88 (0.85, 0.9)                                        $1.72 \times 10^{- 16}$   $5.44 \times 10^{- 12}$   Not available                                                               ---

Note: ---, no data; BMI, body mass index; CI, confidence interval; DNAm, DNA methylation; FDR, false discovery rate.

Linear regression models were fitted using logit-transformed DNAm proportions as dependent variables separately for each CpG and were adjusted, age (y), sex (male/female), BMI (${{kg}/m}^{2}$), Houseman cell proportions (CD8T, CD4T, NK, B cells, monocytes and granulocytes), five genetic principal components and study center (Arizona, Oklahoma, or North and South Dakota).

Not available CpGs in the metanalysis by ([@c40]) reflect that the metanalysis was based in the Illumina Infinium HumanMethylation450 BeadChip array.

Sensitivity Analyses {#s3.3}
--------------------

Results were similar when excluding the eGFR variable from the Cd models. However, we still wanted to keep eGFR in the final model because the filtration rate affects metal levels excreted in the urine ([@c111]). Adjusting for specific gravity slightly attenuated the results but did not change them in a substantial way. In stratified analysis by sex and center for the top 25 DMPs in current smoking models, all the DMPs remained statistically significant and directionally consistent (Tables S4 and S5) except for those from Arizona, where the results where attenuated and 4 of the 25 sites did not reach the statistical significance, probably due to the much smaller sample size in comparison with Oklahoma and North and South Dakota. The contingency table of the self-reported smoking status vs. predicted values by EpiSmokEr can be found in Table S8. Overall, only 1,179 of the 2,325 patients were classified correctly. However, most of the people predicted to be current smokers also reported to be current smokers. We saw similar results when applying RCP and snoob normalizations to those obtained when only applying snoob normalization (data not shown).

Mediation Analysis {#s3.4}
------------------

The number of significant DMPs associated with smoking decreased from 288 to 247 when adjusting for urinary Cd levels (data not shown). The mediated effect in the relationship between current smoking and DNAm through urinary Cd was statistically significant for the six CpGs that were commonly differentially methylated for both Cd and current smoking using the FDR-corrected *p*-values ([Table 4](#t4){ref-type="table"}). Median (minimum, maximum) total effects for the association between current smoking and DNAm were $- 6.83\%$ ($- 13.19\%$, $- 5.70\%$). The corresponding absolute mediated effects through Cd were $- 0.70\%$ ($- 0.88\%$, $- 0.44\%$), respectively. Total effects for former smoking (four CpGs) and cigarette pack-years (six CpGs) and corresponding mediated effects by Cd are shown in Tables S6 and S7. Excel Tables S5, S6, and S7 show mediation analysis for each of the CpGs associated with the smoking variables (current smoking, former smoking, and pack-years).

###### 

Changes in DNA methylation percentages comparing current with never smokers attributable to changes in urinary Cd concentrations ("mediated effect").

Table 4 has 7 main columns, listing CpG, Chr, positions, genes, Functions, Outcome models sup a, and mediated (i.e. indirect) effects sup b of current vs never smoking through cadmium from smoking. The last column of the table is total effects of current vs never smoking in DNA methylation percent. The columns listing Outcome models sup a, and mediated (i.e. indirect) effects sup b of current vs never smoking through cadmium from smoking each have 2 sub columns, listing Absolute changes in DNA methylation percent per log-cadmium unit increase (95 percent C I) and Absolute changes in DNA methylation percent comparing current vs never smokers ("Direct effect") (95 percent C I) and Differences in change attributable to cadmium (95 percent C I) and Percentages of change attributable to cadmium (95 percent C I), respectively.

  CpG          Chr     Position    Gene     Function                                                                             Outcome model[^*a*^](#TF8){ref-type="table-fn"}   Mediated (i.e., indirect) effects[^*b*^](#TF9){ref-type="table-fn"} of current vs. never smoking through Cd from smoking   Total effects of current vs. never smoking in DNA methylation %                         
  ------------ ------- ----------- -------- ------------------------------------------------------------------------------------ ------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------- --------------------- ----------------------------------
  cg14391737   chr11   86513429    PRSS23   Encodes Serine protease 23. May be an important ovarian protease                     $- 2.32$ ($- 2.87$, $- 1.78$)                     $- 5.84$ ($- 6.57$, $- 5.1$)                                                                                               $- 0.88$ ($- 1.14$, $- 0.63$)                                     13.05 (9.4, 17.18)    $- 6.72$ ($- 7.44$, $- 5.99$)
  cg05575921   chr5    373378      AHRR     Mediates dioxin toxicity. Involved in cell growth and differentiation                $- 2.24$ ($- 2.48$, $- 2.01$)                     $- 12.34$ ($- 12.78$, $- 11.89$)                                                                                           $- 0.85$ ($- 1.02$, $- 0.69$)                                     6.43 (5.23, 7.72)     $- 13.18$ ($- 13.64$, $- 12.73$)
  cg21566642   chr2    233284661   2q37.1   Uncharacterized                                                                      $- 1.97$ ($- 2.52$, $- 1.42$)                     $- 8.72$ ($- 9.47$, $- 7.97$)                                                                                              $- 0.74$ ($- 1$, $- 0.51$)                                        7.82 (5.4, 10.6)      $- 9.46$ ($- 10.2$, $- 8.73$)
  cg03636183   chr19   17000585    F2RL3    Blood coagulation, inflammation and response to pain                                 $- 1.73$ ($- 2.17$, $- 1.29$)                     $- 5.04$ ($- 5.64$, $- 4.45$)                                                                                              $- 0.65$ ($- 0.87$, $- 0.46$)                                     11.45 (8.12, 15.33)   $- 5.7$ ($- 6.28$, $- 5.11$)
  cg17739917   chr17   38477572    RARA     Development, differentiation, apoptosis, granulopoeisis, clock genes transcription   $- 1.49$ ($- 2.03$, $- 0.95$)                     $- 6.39$ ($- 7.13$, $- 5.66$)                                                                                              $- 0.56$ ($- 0.8$, $- 0.35$)                                      8.06 (4.97, 11.62)    $- 6.95$ ($- 7.67$, $- 6.24$)
  cg01940273   chr2    233284934   2q37.1   Uncharacterized                                                                      $- 1.16$ ($- 1.55$, $- 0.77$)                     $- 5.29$ ($- 5.82$, $- 4.76$)                                                                                              $- 0.44$ ($- 0.61$, $- 0.28$)                                     7.61 (4.86, 10.73)    $- 5.73$ ($- 6.24$, $- 5.21$)

Note: BMI, body mass index; Cd, cadmium; CI, confidence interval; DNAm, DNA methylation.

Absolute changes (mean differences) in methylation percent comparing current with never smokers (i.e., "Direct effect") and absolute changes in DNAm % associated with one-unit increase in log-transformed urine Cd were both estimated as the regression coefficients from beta models with an identity link (i.e., "Outcome model") which included the following independent variables: current smoking status ("Exposure"), log-transformed Cd ("Mediator"), age (years), sex (men/women), BMI, Houseman cell proportions (CD8T, CD4T, NK, B cells, monocytes and granulocytes), five genetic principal components, and study center (Arizona, Oklahoma, or North and South Dakota).

Effects mediated through Cd (i.e., "Indirect effects") were calculated using the "product of coefficients" method that multiplies the coefficient for the mean difference in log-transformed cadmium concentrations comparing current with never smokers (i.e., 0.38 \[95% CI: 0.32, 0.44\] corresponding to coefficient \[95% CI\] for current smoking status from the linear regression "mediator model" where the outcome is log-transformed Cd adjusted for the same variables as the outcome model, data not shown) by the absolute change in DNAm % associated with one-unit increase in log-Cd concentrations indirect effects were expressed in absolute terms (difference in smoking-related DNAm % change) and relative to the "Total effect" \[DNAm % changes (95% CIs) comparing current with never smokers\] calculated as the sum of the direct and indirect effects. Note that if the mediation analysis assumptions hold, the estimated "Total effects" in the setting of the "product of coefficients" method is numerically identical to the regression coefficient associated with current smoker status in a beta regression as in the outcome model without Cd.

To illustrate the estimation of mediated effects in the setting of the product of coefficients methods, we provide an example: In absolute terms, the mediated effect of Cd in cg14391737 (column 8) was obtained as $- 2.32\,\%$ $\left( {\text{column }6} \right) \times 0.38$ $\,\left( \text{from\ the\ mediator\ model\ mentioned\ above} \right) = - 0.88\,\%$. The corresponding mediated effect in relative terms (column 9) was $- 0.88\,\%/ - 6.72\,\%$$\left( {``\text{Total\ effect}"\text{ from\ column }10} \right) \times 100 = 13.1\,\%$. The 95% CIs for the total and mediated effects were derived by simulation from the estimated model coefficients and covariance matrices.

Enrichment Analyses {#s3.5}
-------------------

Among smoking- and Cd-DMPs with an FDR $p\text{-value} < 0.05$ (6 DMPs for Cd; 288 and 17, respectively, for current and former smoking status; and 77 for cigarette pack-years), we identified a total of 58 GO and 6 KEGG enriched pathways (out of 17,479 GO and 336 and KEGG available gene sets), respectively. The full list of evaluated GO terms and KEGG pathways can be found in Excel Tables S8 and S9. The top 10 GO terms and KEGG pathways were related to cancer (GO:0007229; GO:0071498; GO:0010595; GO:0060574; GO:0005886; GO:0060534; GO:0043149; GO:0002068; hsa05206; hsa04072; hsa05200; hsa05202), CVD and risk factors (GO:0071498; GO:0010595; GO:0060534; GO:0007155; GO:0043149; GO:0002068; GO:0072678; hsa05202; hsa04070; hsa04810), inflammation (GO:0071498; GO:0010595; GO:0007155; GO:0043149); and others (Tables S8 and S9).

Among DMPs with a nominal $p\text{-value} < 10^{- 5}$ (40,443 for Cd; 44,092 for current smoking; 42,000 for former smoking; and 45,612 for pack-years), the molecular enrichment relative to CpG density context (Figure S3, Panel A) showed underrepresentation of CpG Islands for current smoking \[$\text{odds ratio }\left( \text{OR} \right) = 0.36$, $p = 2.4 \times 10^{- 5}$\] and open sea ($\text{OR} = 0.26$, $p = 5.3 \times 10^{- 5}$) for former smoking DMPs. However, CpGs located in S. Shores showed an overrepresentation in former smoking-DMPs ($\text{OR} = 2.96$, $p = 7.4 \times 10^{- 3}$) (Figure S3, Panel B). The enrichment analysis relative to functional gene region revealed some significant findings (Figure S3, Panel B). For current smoking-DMPs, we observed an overrepresentation of sites located at 5′UTR ($\text{OR} = 1.60$, $p = 0.02$) and underrepresentation at first exon ($\text{OR} = 0.50$, $p = 0.02$), TSS200 ($\text{OR} = 0.08$, $p = 7.1 \times 10^{- 8}$) and TSS1500 ($\text{OR} = 0.57$, $p = 0.03$). Cumulative smoking-DMPs showed a statistically significant underrepresentation of TSS200 ($\text{OR} = 0.10$, $p = 5.6 \times 10^{- 3}$). We observed a strong enrichment of several chromatin states for all smoking-related analyses ([Figure 2](#f2){ref-type="fig"}). In particular, there was a consistent over-representation of CpGs in enhancer for current ($\text{OR} = 4.76$, $p = 4.8 \times 10^{- 9}$), former ($\text{OR} = 2.88$, $p = 5.9 \times 10^{- 3}$) and cumulative ($\text{OR} = 4.81$, $p = 4.9 \times 10^{- 7}$) smoking-DMPs.

![Enrichment analysis of top significant cadmium (Cd) and smoking-related differentially methylated positions (DMPs) ($p\text{-value} < 10^{- 5}$) for 15-chromatine states from the ROADMAP project. The area of the solid dots is directly proportional to the strength of the statistical evidence in favor of being annotated to a given chromatin state category comparing statistically significant vs. nonstatistically significant DMPs in our data.](ehp6345_f2){#f2}

*In Silico* Protein-Interaction Analysis {#s3.6}
----------------------------------------

The list of candidate proteins for DNAm-related pathways are shown in Excel Table S10. From the protein--protein interaction, we obtained a network of 271 nodes with 1,802 interactions ([Figures 1](#f1){ref-type="fig"} and [3](#f3){ref-type="fig"}). Among nodes with more than 20 interactions, we mostly found smoking-only nodes (*MYO1G, GFI1*, *CDKN1A*, *GNG12*, and *CYP1B1*), smoking and methylation metabolism nodes (*ANPEP*), and 1 Cd and smoking node (*F2RL3*). Seven smoking-only nodes (*GFI1*, *CYP1B1*, *NFE2L2*, *TSHZ1*, *SIN3B*, *ALPP*, and *ARRB1*) were directly connected to 27 DNAm metabolism nodes. The four Cd and smoking nodes were indirectly connected to DNAm metabolism nodes through six smoking-only nodes. The Cytoscape session is provided so that readers can interactively explore the network (Cytoscape Additional_file.cys supplementary file; publicly available Cytoscape software can be downloaded at <https://cytoscape.org/index.html>), and the general statistics from the Cytoscape file can be found in Excel Tables S11 (network nodes) and S12 (network edges).

![Protein-interaction network between proteins attributed to cadmium (Cd)- and smoking-differentially methylated positions (DMPs) and key proteins in DNA methylation (DNAm) metabolism pathways from KEGG. The nodes correspond to proteins involved in DNAm-related pathways, and proteins encoded by genes associated to Cd-DMPs and smoking-DMPs. The size of the nodes is proportional to the number of connections. The STRING database provides a confidence score (from 0 to 1) to indicate the estimated likelihood that the annotated interaction between a given pair of proteins is biologically meaningful, specific, and reproducible, according to the evidence derived from in-house predictions, homology transfers, and the externally maintained databases ([@c86]). Increasingly darker solid edge lines indicate a protein interaction with increasingly higher confidence scores. The nodes included among the top 25 statistically significant Cd- and/or smoking-DMPs in our EWAS show thicker node lines.](ehp6345_f3){#f3}

Discussion {#s4}
==========

After a conservative FDR correction, we found DMPs associated with current smoking, cumulative smoking dose, and urinary Cd levels, being all Cd-DMPs also smoking-DMPs. We replicated the association of well-established smoking-associated DNAm sites, including sites mapped to the genes *AHRR*, *F2RL3*, *PRSS23*, *RARA*, and 2q37.1. In addition, we found several smoking-associated DMPs that had not been previously reported. Our mediation analysis supports that Cd is a partial mediator of the association between smoking and differential DNAm at specific sites. The integrative *in silico* analysis provides further support for interconnected epigenetic mechanisms of both Cd- and smoking-associated health effects, including the possibility of Cd influencing smoking-related DNAm changes at relevant loci.

A large evidence base supports the association between smoking and differential methylation of several genes, with *AHRR*, *F2RL3*, and 2q37.1 being the most documented ([@c8]; [@c27]; [@c29]; [@c40]; [@c71]; [@c109]). Little is known about the 2q37.1 region. Although it is one of the most commonly deleted subtelomeric regions ([@c49]), the health implications of the differential methylation in this region are not clear. The two Cd-related DMPs located in this region were no longer significant when restricting the Cd models to never smokers, whereas all the other DMPs were still significant among never smokers.

Whether epigenetic modifications are a biological mechanism for well-known smoking-related health effects remains a focus of ongoing investigations. In fact, altered DNAm of *AHRR* and *F2RL3* has been suggested to be part of the biological links between cigarette smoking and several diseases, especially lung cancer and atherosclerosis ([@c71]), in addition to being strong predictors of all-cause mortality in several studies ([@c17]; [@c27]; [@c110]). Other smoking-related DMPs in our data such as *CPOX*, *KIAA0087*, *PRSS23*, *GPR15*, and *RARA*, among others, have also been consistently documented ([@c35]; [@c94]).

Two different Illumina microarrays have been used in previous studies, the Illumina Infinium HumanMethylation27 BeadChip array (which interrogates DNAm at 27,000 CpGs located mostly in promoter regions) and Illumina HumanMethylation450 BeadChip array (including 450,000 CpGs). This is the first human study to use the Illumina Infinium MethylationEPIC BeadChip array to assess differential DNAm in relation to smoking, which led to novel insights. For instance, some new genes that warrant further investigation include a zinc finger protein (ZNF83), with a role of coordinating zinc ions ([@c11]), *PTPN1*, which is involved in oncogenic transformations ([@c112]), and *RAB32*, a member of the RAS oncogene family, whose overexpression has been shown in 20% to 25% of all human tumors and up to 90% in pancreatic cancer ([@c23]). For former smoking, however, we only found six significant CpGs, which indicates that current smoking is more relevant for methylation changes than former smoking. In fact, several studies suggested that methylation changes associated to smoking can be reversed on cessation ([@c51]; [@c94]). It is interesting to note that significant current, former, and cumulative smoking-DMPs were enriched in several categories of blood-specific enhancer regions. These findings support the hypothesis that identified DMPs may be biologically relevant, because it is known that enhancers regulate gene expression in a tissue-specific manner, in this case blood, which is our target tissue. Overall, our findings from molecular regulatory elements enrichment analysis are consistent with the hypothesis of epigenetic dysregulations being involved in mechanisms by which smoking induces diseases.

An interesting aspect is that Cd exposure has been consistently associated with several human health disorders in common with smoking, including CVD ([@c16]; [@c88]) and several types of cancer ([@c30]; [@c53]), as well as kidney disease ([@c32]; [@c58]; [@c64]), bone disease ([@c2]; [@c13]), and premature mortality ([@c45]). Cd has also been related to biomarkers of inflammation ([@c26]) and oxidative stress ([@c22]; [@c59]) in epidemiological studies. Given that smoking is known to be a major source of Cd exposure ([@c62]), several studies have assessed whether Cd could be a mediator between smoking and adverse health effects. In a study conducted in a Swedish cohort ([@c3]), about two-thirds of the association between smoking and atherosclerosis was found to be mediated by Cd. In a representative sample of the U.S. general population, Cd partially explained the association of smoking on peripheral arterial disease, which is characterized by the atherosclerotic narrowing of the arteries of the lower extremities ([@c57]). Cd also displayed a potential role as mediator of the association between smoking and lung cancer ([@c30]).

To our knowledge, however, no studies have evaluated the potential mediating role of Cd in the association between smoking and DNAm. This hypothesis is relevant, given the increasing evidence on the connection of DNAm with relevant biological pathways by which environmental exposures could cause disease. Although some studies have assessed the potential effects of Cd exposure in DNAm, many of them were conducted in experimental settings or interrogated only a reduced number of specific CpGs and genes ([@c74]). Few EWAS, however, have been conducted for Cd exposure in adults. None of our DMPs for Cd have been found in previous studies; nevertheless, these studies were not comparable with ours. One EWAS involved placental Cd and placental DNAm and is therefore not comparable to blood DNAm given the tissue-specificity of DNAm ([@c25]). Another EWAS specifically looked at differences in DNAm age by urinary Cd concentrations ([@c20]). A study evaluated DNAm differences associated with Cd in 4.6 million CpGs. However, the sample size was very small ($n = 17$), and none of the sites were significant after correcting for multiple comparisons, so top hits may be unstable ([@c76]). In our data, changes in Cd levels from smoking were associated to DNAm changes in the most broadly known smoking-associated genes, suggesting common epigenetic dysregulations due to smoking and Cd exposure at these sites. Nonetheless, only 6 DMPs were found for Cd as opposed to the 288 found for current vs. never smoking. There are more than 7,000 chemicals in cigarette smoke, from which 93 are classified as harmful and potentially harmful constituents (HPHCs), which include Cd and other metals ([@c55]). More studies exploring the epigenetic effects of other harmful chemicals from smoking are needed.

The protein--protein interaction network, on the other hand, deepens into the potentially close relationship between DNAm metabolism pathways and genes attributed to smoking and Cd-DMPs. For instance, the Aminopeptidase N (*ANPEP*), which belongs to the glutathione metabolism pathway showed the highest number of connections (directly interacting with 16 other methylation-related proteins and 15 smoking nodes including *F2RL3* and *RARA*, also associated with Cd). It is interesting to note that negative *APN* (the ANPEP encoded protein) immunoreactivity has been suggested as a prognostic factor for prostate cancer ([@c80]), which has been associated with both Cd and smoking ([@c30]; [@c95]). Moreover, the *F2RL3* gene, which encodes a protease-activated receptor that plays a role in blood coagulation, inflammation, response to pain, and cancer, is also highly connected in the network and directly interacts with *RARA*, which has been associated with increased sensitivity to retinoids in T-cell lymphoma in experimental settings ([@c101]). Other highly connected smoking-DMPs in the network, such as *MYO1G*, *GFI1*, *CDKN1A*, *GNG12*, and *CYP1B1*, have been previously reported as smoking-DMPs in other epigenetic studies ([@c31]; [@c83]; [@c84]; [@c103]) and have also been implicated in cancer ([@c33]; [@c56]; [@c105]) or cardiometabolic diseases ([@c21]; [@c65]). All of them are directly connected to Cd-associated nodes.

Our study has some limitations. First, because smoking is a major source of Cd, and smoking status was based on self-report, a possible concern is whether Cd serves as a biomarker of tobacco exposure rather than reflecting Cd per se. However, in a confirmatory sensitivity analysis for the Cd-associated DMPs among never smokers, we found that four of the six signals remained significant after excluding current and former smokers. This supports the hypothesis that Cd in urine could come from other exposure sources such as diet. A previous study ([@c63]) evaluated the association between several dietary products and urinary Cd levels in the SHS, reporting the potential importance of processed meat products as a dietary source of Cd. Occupational exposure to Cd occurs mainly during mining, smelting, and work with Cd-containing minerals ([@c5]). We do not have occupational data in our study; however, some people might do handmade work with minerals and Cd pigments (e.g., jewelry making) and might be exposed to Cd that way. In addition, secondhand tobacco smoke exposure could also be related to urinary Cd levels in never smokers. In a sensitivity analysis with EpiSmokEr, most of the misclassification was from participants who self-reported to be former smokers but for which the algorithm predicted them to be never smokers. Given that it is unlikely that people would indicate they smoked in the past without doing it (i.e., reporting to be a former smoker when he or she is a never smoker), this aspect could be related to the previously reported reversible nature of some of the smoking-related epigenetic marks ([@c71]). In the same way, many self-reported current smokers were predicted to be former smokers by the algorithm. This prediction could be related to the small number of cigarettes per day smoked by many smokers in our population (median cigarette pack was 4, which would mean that one person could have smoked, for example, 2 cigarettes per day through 40 y, or 4 cigarettes per day through 20 y). Finally, we cannot discard misclassification due to secondhand smoke, because in this study there was a median (IQR) of 1 (0, 6) h of self-reported exposure to secondhand smoke per day. In addition, mediation analysis is subject to strong assumptions ([@c66]; [@c96]), for instance, the assumption of no unmeasured confounders. Residual confounding cannot be discarded in observational studies. It is important to note that we obtained essentially identical mediated effects when we used the difference of coefficient methods instead of the product of coefficient methods (data not shown), which indicates that the no exposure-mediator interaction assumption holds in our data.

Another limitation is the fact that we conducted mediation analysis in the setting of a cross-sectional study design. However, cigarettes are known to contain Cd, so the directionality between smoking and Cd exposure relation over time is clear. The directionality between Cd exposure and blood DNAm is less clear, but---given the long half-life of urinary Cd (15--30 y) and the fact that Cd is an exogenous nonessential metal---it is likely that Cd exposure precedes blood DNAm. Finally, although replication of results in independent study populations is required in studies conducting genomic explorations of the methylome, this concern may be a relatively minor one in our case, given the robustness of our data with respect to well-replicated smoking-related signals across a wide range of other population studies ([@c29]; [@c41]).

The strengths of our study include the large sample size, including methylation data for the largest amount of CpGs possible with current microarray technology (Illumina Infinium MethylationEPIC BeadChip); the high quality of the study protocols; and the availability of information to account for potential confounders.

In conclusion, this work supports the hypothesis that Cd, one of the principal toxicants in cigarettes, could be partially explaining well-established associations of smoking with DNAm changes. Cd exposure could thus be linked to smoking adverse health outcomes through epigenetic mechanisms. Although smoking exposure has declined in recent decades, public health interventions are still needed for controlling smoking exposure among the population. Additional strategies are also needed to reduce Cd exposure from other sources beyond tobacco ([@c75]). Findings from our *in silico* study needs functional confirmation in experimental settings, as relevant proteins in our protein-interaction network can contribute to the understanding of Cd and smoking-related adverse health outcomes and mechanisms.
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